These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29318966)

  • 21. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
    Späh F
    Br J Dermatol; 2008 Aug; 159 Suppl 2():10-7. PubMed ID: 18700910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients.
    Maes M; Ruckoanich P; Chang YS; Mahanonda N; Berk M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):769-83. PubMed ID: 20561554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity?
    Giles JT
    Curr Rheumatol Rep; 2016 May; 18(5):27. PubMed ID: 27032790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis.
    Mahmoudi M; Aslani S; Fadaei R; Jamshidi AR
    Int J Rheum Dis; 2017 Mar; 20(3):287-297. PubMed ID: 28205331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target.
    Golia E; Limongelli G; Natale F; Fimiani F; Maddaloni V; Pariggiano I; Bianchi R; Crisci M; D'Acierno L; Giordano R; Di Palma G; Conte M; Golino P; Russo MG; Calabrò R; Calabrò P
    Curr Atheroscler Rep; 2014 Sep; 16(9):435. PubMed ID: 25037581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory joint diseases and atherosclerosis: time to look beyond the 'lipid paradox'.
    Mackey RH; Kuller LH; Moreland LW
    Curr Opin Lipidol; 2019 Aug; 30(4):342-349. PubMed ID: 31145122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atherosclerosis and rheumatoid arthritis: more than a simple association.
    Cavagna L; Boffini N; Cagnotto G; Inverardi F; Grosso V; Caporali R
    Mediators Inflamm; 2012; 2012():147354. PubMed ID: 23024462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial dysfunction in chronic inflammatory diseases.
    Steyers CM; Miller FJ
    Int J Mol Sci; 2014 Jun; 15(7):11324-49. PubMed ID: 24968272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment.
    Kerola AM; Rollefstad S; Semb AG
    Eur Cardiol; 2021 Feb; 16():e18. PubMed ID: 34040652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis.
    Dragoljevic D; Westerterp M; Veiga CB; Nagareddy P; Murphy AJ
    Clin Sci (Lond); 2018 Sep; 132(17):1889-1899. PubMed ID: 30185612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation.
    Miller AM; McInnes IB
    Curr Pharm Des; 2011; 17(1):1-8. PubMed ID: 21222645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives.
    Lindhardsen J; Kristensen SL; Ahlehoff O
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):1-8. PubMed ID: 26293235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory arthritis as a novel risk factor for cardiovascular disease.
    John H; Kitas G
    Eur J Intern Med; 2012 Oct; 23(7):575-9. PubMed ID: 22841864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opportunities for the treatment of inflammation in cardiovascular disease.
    Crossman DC
    Expert Opin Pharmacother; 2001 Nov; 2(11):1751-63. PubMed ID: 11825314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapeutic strategies for chronic inflammatory diseases.
    Ferrer E
    Drug News Perspect; 2006; 19(6):353-8. PubMed ID: 16971972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory disorders and atherosclerosis: new therapeutic approaches.
    Charakida M; O'Neil F; Masi S; Papageorgiou N; Tousoulis D
    Curr Pharm Des; 2011 Dec; 17(37):4111-20. PubMed ID: 22204372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostanoids and NSAIDs in cardiovascular biology and disease.
    Weksler BB
    Curr Atheroscler Rep; 2015 Jul; 17(7):41. PubMed ID: 26017392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications.
    Sirmans SM; Weidman-Evans E; Everton V; Thompson D
    Ann Pharmacother; 2012 Mar; 46(3):403-18. PubMed ID: 22388330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.